First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million First-Quarter 2021 Orphan Segment Net Sales Increased
Share this article
Share this article
NEW YORK, March 8, 2021 /PRNewswire/ The Alzheimer s Drug Discovery Foundation (ADDF) announced today that four of its funded researchers will be making presentations at the 15
th International Conference on Alzheimer s and Parkinson s Diseases (AD/PD™ 2021), which will be held virtually from Barcelona, Spain March 9-14, 2021. The ADDF seeks out and maintains a diverse portfolio of novel drug and biomarker targets that reflect the many biological pathways implicated in Alzheimer s disease, said Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF. We are excited to hear the latest updates from these investigators on some of the novel approaches we have supported since the early phases of research.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
ADDF-Funded Investigators to Present Findings at Next Week’s Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 21)
March 8, 2021 GMT
(PRNewsfoto/ADDF)
NEW YORK, March 8, 2021 /PRNewswire/ The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that four of its funded researchers will be making presentations at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 21), which will be held virtually from Barcelona, Spain March 9-14, 2021.
“The ADDF seeks out and maintains a diverse portfolio of novel drug and biomarker targets that reflect the many biological pathways implicated in Alzheimer’s disease,” said Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF. “We are excited to hear the latest updates from these investigators on some of the novel approaches we have supported since the early phas